Immune dysregulation and targeting in MDS
VJHemOnc Podcast
00:00
Future Treatments and Targeting in MDS and AML
Discussion on potential future treatments for low-risk and high-risk MDS and AML, including the use of inflamisone inhibitors, changing treatments with new mutations, metronomic therapy, and targeting the immune system. Emphasis on higher quality remissions, MRD in MDS, and the need for triplet or quadruplet studies while balancing toxicity.
Play episode from 07:51
Transcript
